Successful treatment with convalescent plasma inCovid-19 disease in relaps/refractory multiple myeloma

Basit Öğe Kaydı
dc.contributor.authorSarıcı, Ahmet
dc.contributor.authorBiçim, Soykan
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorBerber, İlhami
dc.contributor.authorKaya, Emin
dc.contributor.authorKuku, İrfan
dc.contributor.authorOzgul, Mustafa
dc.date.accessioned2024-08-04T19:42:39Z
dc.date.available2024-08-04T19:42:39Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus detected in the Wuhan Province of the People's Republic of China caused a pandemic in a very short time all over the world. Convalescent plasma (CP) therapy is a passive antibody therapy that has been shown to be effective in epidemic periods. CP therapy has been of interest in the treatment of infection with no vaccine or specific treatment, such as the Sars-CoV-2 infection that causes COVID-19. We aimed to report our CP experience in Sars-Cov-2 infection in our relapsed / refractory Multiple myeloma (MM) patient.en_US
dc.identifier.doi10.5455/annalsmedres.2021.02.191
dc.identifier.endpage2241en_US
dc.identifier.issn2636-7688
dc.identifier.issue12en_US
dc.identifier.startpage2239en_US
dc.identifier.trdizinid514741en_US
dc.identifier.urihttps://doi.org/10.5455/annalsmedres.2021.02.191
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/514741
dc.identifier.urihttps://hdl.handle.net/11616/88553
dc.identifier.volume28en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleSuccessful treatment with convalescent plasma inCovid-19 disease in relaps/refractory multiple myelomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu